Mark Yen MD

Family Medicine•Glendale, CA

Physician

Join to View Full Profile

1560 E Chevy Chase DrSuite 140Glendale, CA 91206
Phone+1 818-409-8000

Education & Training

Kaiser Permanente Southern California (Los Angeles)Residency, Family Medicine, 2000 - 2003
Albert Einstein College of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2001 - 2019

Clinical Trials

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers Start of enrollment: 2008 Aug 01
Completed
Phase 1
AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects Start of enrollment: 2008 Oct 01
Completed
Phase 1
AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects Start of enrollment: 2008 Nov 01
Completed
Phase 1
AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects Start of enrollment: 2009 May 01
Completed
Phase 1
AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects Start of enrollment: 2009 Jul 01
Terminated
Phase 1
AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects Start of enrollment: 2010 Apr 01
Completed
Phase 1
A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects Start of enrollment: 2010 Jul 01
Completed
Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects Start of enrollment: 2011 Feb 01
Completed
Phase 1
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort Start of enrollment: 2010 Dec 01
Completed
Phase 1
Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects Start of enrollment: 2011 May 01
Suspended
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical stu...
Paul D. Martin, S. Y. Amy Cheung, Mark Yen, David Han, Michael Gillen
European Journal of Clinical Pharmacology. 2016-01-01
13 citations
Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.
Patrick Scoble, Robert C. Owens, Sailaja Puttagunta, Mark Yen, Michael W. Dunne
Clinical Drug Investigation. 2015-10-12